Tirzepitide GLP-2T (10mg)

Dual receptor research — precision-engineered peptide innovation.

• Tirzepitide is a novel dual-acting peptide analog targeting both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors.
• Extensively studied in controlled research for its potential influence on metabolic regulation and energy balance pathways.
• Independently verified by Vanguard Laboratory for identity and purity.

Tirzepitide is a synthetic linear peptide acting as a dual GIP/GLP-1 receptor agonist. It has been studied for its ability to modulate glucose metabolism and energy regulation.

Preclinical studies indicate activation of both receptor pathways can enhance insulin sensitivity, improve glycemic control, and reduce adiposity in animal models

Clinical research on Tirzepitide (SURPASS trials) has investigated its multi-receptor mechanism in metabolic pathways

Regulatory Status: Tirzepitide is not FDA-approved for human or veterinary use outside regulated contexts. This product is supplied strictly for laboratory research only.